After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the ...

GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review a Biologics License Application, BLA, for Blenrep in combinations with bortezomib plus dexamethasone and ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...